False Promise of Vaginal Laser Therapy in Breast Cancer Survivors Debunked

Core Concepts

Vaginal laser therapy does not improve symptoms of genitourinary syndrome of menopause (GSM) or sexual function in breast cancer survivors.

Abstract

The content discusses a randomized controlled trial that disproves the effectiveness of vaginal laser therapy in relieving symptoms of GSM and enhancing sexual function in breast cancer survivors. Despite the evidence, practitioners may continue to promote this therapy due to financial incentives. The study highlights the lack of FDA clearance for these laser devices and the limited evidence supporting their safety and efficacy. The trial involved breast cancer survivors with GSM, showing no significant differences between real and sham laser therapy in improving outcomes related to GSM.

Stats

"many practitioners here and around the world will likely continue to use the offensive 'vaginal rejuvenation' language to coax patients into paying thousands of dollars to treat GSM for what the most robust current evidence tells us is an ineffective procedure," Gunter said.
"There is simply too much money to be made."
"The study "should have been enough to pause laser therapy outside of clinical trials. Unfortunately, it was not," Gunter said.

Quotes

"I'll say it again people: these cash-based 'rejuvenation' therapies are no better than placebo."

Key Insights Distilled From

False Promise of Vaginal Laser Therapy in Breast Cancer Survivors

by Megan Brooks at www.medscape.com 04-13-2023

https://www.medscape.com/viewarticle/990725

Deeper Inquiries

Will the lack of FDA intervention lead to continued promotion of ineffective vaginal laser therapy?

The lack of FDA intervention is likely to contribute to the continued promotion of ineffective vaginal laser therapy. As highlighted in the context, practitioners may prioritize profit over evidence-based practice, leading them to ignore research findings that discredit the efficacy of such therapies. Without regulatory oversight from the FDA, practitioners may continue to market vaginal laser therapy as a viable option for treating genitourinary syndrome of menopause (GSM) or improving sexual function, despite the lack of substantial evidence supporting its effectiveness. This situation underscores the importance of regulatory bodies in ensuring that medical interventions are safe and efficacious before being promoted to the public.

Is there a potential ethical concern with practitioners profiting from therapies proven to be ineffective?

There is indeed a significant ethical concern with practitioners profiting from therapies that have been proven to be ineffective. When healthcare providers offer treatments that lack scientific support or evidence of efficacy, they are essentially exploiting vulnerable patients who may be seeking relief from distressing symptoms. By charging patients substantial amounts of money for procedures that do not deliver the promised benefits, practitioners are engaging in unethical behavior that prioritizes financial gain over patient well-being. This exploitation erodes trust in the medical profession and can have detrimental effects on patients' physical and emotional health.

How can patients be better informed about the risks and benefits of vaginal laser therapy?

Patients can be better informed about the risks and benefits of vaginal laser therapy through transparent and comprehensive communication from healthcare providers. It is crucial for practitioners to engage in open discussions with patients, clearly explaining the current evidence regarding the effectiveness of laser therapy for genitourinary syndrome of menopause (GSM) and sexual function. Patients should be informed about the lack of FDA approval for these devices and the limited safety and efficacy data available. Additionally, practitioners should discuss alternative treatment options supported by robust scientific evidence, empowering patients to make informed decisions about their healthcare. Providing patients with access to reliable information, encouraging them to ask questions, and involving them in shared decision-making processes can help ensure that they are well-informed about the potential risks and benefits of vaginal laser therapy.